IgniteData, the leading clinical research data technology company transforming how healthcare data flows into clinical trials, today announced the significant global expansion of its flagship platform, Archer. Now deployed across a rapidly growing roster of the world’s most prestigious research institutions, Archer is setting the standard for real-time, regulatory-grade EHR-to-EDC or eSource to Sponsor automation. IgniteData has built Archer to go beyond minimum regulatory expectations, reflecting its commitment to setting higher standards for the industry.
Rapid Growth and Global Reach
In the past 12 months alone, the Archer Platform has been expanded to many of the leading Academic Medical Centers across the globe, encompassing a range of specialties, including Cardiovascular, Endocrinology, and Oncology. 70% of the NCI-designated cancer centers, including 8 of the top 10 on the US News and World Report’s 2025 rankings, have adopted or are in the process of adopting Archer, underscoring its position as the trusted solution for advanced clinical trial data transfer. Deployments span the United States, Canada, Europe, and Australia, with near-term entries in Latin America, Asia, and the Middle East.
IgniteData has seen remarkable growth in its site network: the Archer Network increased by 250% in 2024 and has already grown by 287% in 2025. Looking ahead to the end of 2025, IgniteData estimates that it will reach over 50 of the leading research centers and community networks, representing more than 1,000 sites globally. This hypergrowth puts IgniteData among the fastest-growing Healthcare IT companies.
“One of the key factors to this hypergrowth and adoption by leading research centers is the ease of the initial deployment of Archer, and the simplicity of adding new investigator-initiated trials (IITs) and studies from sponsors,” said Dr. Jose Galvez, CMIO of IgniteData and former Deputy Director, FDA. “We have seen a reduction of the initial install go from weeks to days, and onboarding new studies from days to hours, creating a truly scalable, vendor-agnostic platform.”
Site-Centric, Vendor Agnostic, with Enterprise-Scale Performance
IgniteData acts as the connective tissue layer between sites and sponsors. The Archer Platform enables real-time transfer of source data, such as EHRs (Epic, Cerner, etc.), directly into sponsor databases like EDCs (Medidata, Veeva, etc.), significantly reducing manual transcription while ensuring full auditability. Built for interoperability, Archer supports consistent deployments across diverse healthcare systems, helping sponsors and sites streamline operations at scale. Seamlessly embedded within site workflows, Archer significantly reduces coordinator burden, preserves regulatory compliance, and safeguards data provenance.
“It’s not about transferring 100% of the source data resulting in a huge bolus of unusable data, which often exceeds what the patient consented to,” says Dr. Galvez. “It’s about surfacing the correct and accurate data, at the right time, with full provenance and auditability.”
The Archer Platform does not persist data or create shadow databases; rather, it maintains data privacy and sovereignty while ensuring complete auditability and provenance. Not only does Archer meet all current regulatory standards, but it goes further — setting a new benchmark for data quality and patient safety. While fully compliant with global regulatory requirements, it is designed to exceed these standards, ensuring organizations are future-ready as eSource to Sponsor evolves in the rapidly changing healthcare and life sciences ecosystem.
Leadership Perspective
“Expanding into the world’s most respected research institutions is proof that Archer is not just another technology—it’s the new standard for clinical trial data automation,” said Zach Taft, Chief Executive Officer, IgniteData. “By surpassing regulatory guidelines, Archer gives sponsors and research sites added confidence in data accuracy, accelerating studies while reducing risk and optimizing budgets. At the end of the day, it’s about delivering better and safer therapies to patients worldwide.”
